---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-032959"
form_type: "8-K"
ticker: "OVID"
cik: "0001636651"
company_name: "Ovid Therapeutics Inc."
filed_at: "2025-06-25T23:59:59+00:00"
generated_at: "2026-05-18T19:24:48.022235+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Ovid sells future ganaxolone royalties to Immedica for $7.0M cash

## Summary
- Immedica pays $7.0M to acquire 100% of Ovid's royalty rights on ganaxolone sales outside China.
- Ovid recorded ~$566K in ganaxolone royalty revenue in 2024; deal provides non-dilutive funding.
- Immedica also obtains additional ganaxolone IP rights and assumes future IP costs.
- Transaction expands Immedica's control of ganaxolone; no impact on Ovid's pipeline.
- Amended license expected within six months to broaden field and territory.

## SEC filing metadata
- accession: 0001628280-25-032959
- form_type: 8-K
- ticker: OVID
- cik: 0001636651
- company_name: Ovid Therapeutics Inc.
- filed_at: 2025-06-25T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1636651/000162828025032959/0001628280-25-032959-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1636651/000162828025032959/ovid-20250625.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-032959
- JSON: https://secwatch.observer/filing/0001628280-25-032959.json
- Plain text: https://secwatch.observer/filing/0001628280-25-032959.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.